---
title: "ImageneBio (IMA) news: offering and merger"
url: "https://aibio.space/companies/imagenebio/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "IMA offering and merger news: ImageneBio agrees to sell pre-funded warrants for about $30 million in private placement. ImageneBio, Inc."
---

IMA ImageneBio, Inc. NASDAQ · United States

# ImageneBio (IMA) news IMA offering and merger news

Financings · 2026-04-13

## [ImageneBio agrees to sell pre-funded warrants for about $30 million in private placement](https://aibio.space/news/imagenebio-agrees-sell-pre-funded-warrants-about-30-million-private/)

The warrants cover up to 5,770,335 shares at $5.199 per warrant share, with closing expected on or about April 14, 2026. ImageneBio plans to use the proceeds for its IMG-007 programs.

## Latest ImageneBio news

1. 2025-07-29 Mergers [Ikena Oncology (now ImageneBio) completes Inmagene merger, issues contingent value rights](https://aibio.space/news/ikena-oncology-now-imagenebio-completes-inmagene-merger-issues/) Ikena Oncology, now ImageneBio, closed its merger with Inmagene Biopharmaceuticals on July 25, 2025. It issued contingent value rights to both sets of shareholders, which pay only from proceeds of selected assets, and it took on a transition services deal with a company owned by Inmagene's legacy holders.
2. 2025-07-29 Mergers [ImageneBio says Ikena Oncology and Imagene merger completed in July 2025](https://aibio.space/news/imagenebio-says-ikena-oncology-imagene-merger-completed-july-2025/) A July 2025 corporate overview says the merger closed and that the company has raised $140 million to date. Its lead drug, IMG-007, is in a Phase 2b trial in atopic dermatitis.
3. 2025-07-01 Mergers [Ikena Oncology (now ImageneBio) files merger partner Inmagene's Phase 2b trial start](https://aibio.space/news/ikena-oncology-now-imagenebio-files-merger-partner-inmagenes-phase-2b/) Inmagene dosed the first patient in its ADAPTIVE trial of IMG-007 in atopic dermatitis, with topline results expected in the fourth quarter of 2026. Ikena filed the news as merger material.

## ImageneBio at a glance

- **Ticker**: IMA

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $136.2 million

### Related companies

- [Celldex Therapeutics](https://aibio.space/companies/celldex-therapeutics/) NASDAQ: CLDX
- [First Tracks Biotherapeutics](https://aibio.space/companies/first-tracks-biotherapeutics/) NASDAQ: TRAX
- [Heron Therapeutics](https://aibio.space/companies/heron-therapeutics/) NASDAQ: HRTX
- [UroGen Pharma](https://aibio.space/companies/urogen-pharma/) NASDAQ: URGN
- [Lineage Cell Therapeutics](https://aibio.space/companies/lineage-cell-therapeutics/) AMEX: LCTX
- [Vaccinex](https://aibio.space/companies/vaccinex/) OTC: VCNX
- [Aridis Pharmaceuticals](https://aibio.space/companies/aridis-pharmaceuticals/) OTC: ARDS
- [Lexeo Therapeutics](https://aibio.space/companies/lexeo-therapeutics/) NASDAQ: LXEO

### Also on NASDAQ

- [Immunome](https://aibio.space/companies/immunome/) IMNM
- [Personalis](https://aibio.space/companies/personalis/) PSNL
- [Amphastar Pharmaceuticals](https://aibio.space/companies/amphastar-pharmaceuticals/) AMPH
- [Aura Biosciences](https://aibio.space/companies/aura-biosciences/) AURA
- [Aldeyra Therapeutics](https://aibio.space/companies/aldeyra-therapeutics/) ALDX
- [MERIT MEDICAL SYSTEMS INC](https://aibio.space/companies/merit-medical-systems/) MMSI

## ImageneBio annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$800,000](https://www.sec.gov/Archives/edgar/data/1835579/000119312526099434/) | [$3.5 million](https://www.sec.gov/Archives/edgar/data/1835579/000119312526099434/) |
| Research and development | [$28.5 million](https://www.sec.gov/Archives/edgar/data/1835579/000119312526099434/) | [$32.1 million](https://www.sec.gov/Archives/edgar/data/1835579/000119312526099434/) |
| Net income (loss) | [-$45.3 million](https://www.sec.gov/Archives/edgar/data/1835579/000119312526099434/) | [-$36.6 million](https://www.sec.gov/Archives/edgar/data/1835579/000119312526099434/) |
| Cash from operations | [-$47.8 million](https://www.sec.gov/Archives/edgar/data/1835579/000119312526099434/) | [-$21.3 million](https://www.sec.gov/Archives/edgar/data/1835579/000119312526099434/) |
| Cash and equivalents | [$94.5 million](https://www.sec.gov/Archives/edgar/data/1835579/000119312526333920/) | [$12.1 million](https://www.sec.gov/Archives/edgar/data/1835579/000119312526099434/) |
| Short-term investments | [$40.8 million](https://www.sec.gov/Archives/edgar/data/1835579/000119312526333920/) | [$0](https://www.sec.gov/Archives/edgar/data/1835579/000119312526099434/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $94.7 million, plus short-term investments of $41.5 million, $136.2 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about ImageneBio

Has ImageneBio raised money recently?

Our latest story on this, dated Apr 13, 2026: "ImageneBio agrees to sell pre-funded warrants for about $30 million in private placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/imagenebio-agrees-sell-pre-funded-warrants-about-30-million-private/).

Is ImageneBio involved in a merger or acquisition?

Our latest story on this, dated Jul 29, 2025: "Ikena Oncology (now ImageneBio) completes Inmagene merger, issues contingent value rights". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ikena-oncology-now-imagenebio-completes-inmagene-merger-issues/).

What is the ticker symbol of ImageneBio?

ImageneBio, Inc. trades under the ticker IMA on NASDAQ.

Where is ImageneBio listed?

ImageneBio, Inc. is listed on NASDAQ.

What is the SEC CIK of ImageneBio?

The SEC Central Index Key (CIK) for ImageneBio, Inc. is 1835579. Its filings are on SEC EDGAR.

How many shares does ImageneBio have outstanding?

11,351,456 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05.

Which country or territory is ImageneBio listed under?

Our directory records ImageneBio, Inc. under United States.

What does ImageneBio do?

Our directory classifies ImageneBio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of ImageneBio?

The ISIN recorded for ImageneBio, Inc. is US45175G2075.

Does aibio.space cover ImageneBio?

aibio.space lists ImageneBio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is ImageneBio incorporated?

SEC records list its state or country of incorporation as DE.

What was ImageneBio's revenue last year?

$800,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is ImageneBio profitable?

ImageneBio, Inc. reported a net loss of $45.3 million for the fiscal year ended Dec 31, 2025, and used $47.8 million of cash in operations, per its annual report to the SEC.

How much does ImageneBio spend on research and development?

$28.5 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does ImageneBio have?

$136.2 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.

## Investor discussion: ImageneBio

Members talk about ImageneBio (IMA). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at ImageneBio, newest first. Each line links the filing it comes from.

1. 2026-08-05 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1835579/000119312526335213/d150354ds3.htm)
2. 2026-04-30 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1835579/000114036126018267/edge20064682x1_def14a.htm)
3. 2026-04-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1835579/000119312526151942/d143873d8k.htm)
4. 2025-10-29 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02). [Source](https://www.sec.gov/Archives/edgar/data/1835579/000119312525254697/d24830d8k.htm)
5. 2025-09-08 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1835579/000119312525198360/d931520ds1.htm)
6. 2025-08-05 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1835579/000119312525173626/d88091d8k.htm)
7. 2025-08-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1835579/000119312525171747/d96158dex991.htm)
8. 2025-07-29 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,5.01,5.02,5.03,5.06,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1835579/000119312525167089/d66290dex991.htm)
9. 2025-07-24 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1835579/000119312525163990/d21564d8k.htm)
10. 2025-07-15 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1835579/000119312525159400/d42277dex991.htm)
11. 2025-07-01 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1835579/000119312525154016/d917926dex991.htm)
12. 2024-12-23 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,5.01,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1835579/000119312524283722/d889670dex991.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:IMA on TradingView](https://www.tradingview.com/symbols/NASDAQ-IMA/).

## SEC filings and registration

- **SEC name**: ImageneBio, Inc.

- **CIK**: 1835579

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: IMA (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

- **Business address**: 12526 HIGH BLUFF DRIVE, SAN DIEGO, CA, 92130

- **Phone**: 857-343-8292

- **Shares outstanding**: 11,351,456 as of 2026-07-31 (10-Q filed 2026-08-05)

- **Former names**: Ikena Oncology, Inc.

### Recent filings (8-K and 6-K are the company's own announcements)

- [S-3](https://www.sec.gov/Archives/edgar/data/1835579/000119312526335213/d150354ds3.htm) filed 2026-08-05
- [S-3](https://www.sec.gov/Archives/edgar/data/1835579/000119312526335163/d108167ds3.htm) filed 2026-08-05
- [10-Q](https://www.sec.gov/Archives/edgar/data/1835579/000119312526333920/ima-20260630.htm) filed 2026-08-05
- [8-K](https://www.sec.gov/Archives/edgar/data/1835579/000119312526333912/d166048d8k.htm) filed 2026-08-05
- [8-K](https://www.sec.gov/Archives/edgar/data/1835579/000119312526314167/d143178d8k.htm) filed 2026-07-23
- [8-K](https://www.sec.gov/Archives/edgar/data/1835579/000119312526285424/d131079d8k.htm) filed 2026-06-26
- [8-K](https://www.sec.gov/Archives/edgar/data/1835579/000119312526274139/d114862d8k.htm) filed 2026-06-17
- [10-Q](https://www.sec.gov/Archives/edgar/data/1835579/000119312526212073/ima-20260331.htm) filed 2026-05-07

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001835579), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

ImageneBio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IMA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: ImageneBio, Inc.

- **Ticker**: IMA

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US45175G2075

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-IMA/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/imagenebio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ImageneBio (IMA) news: offering and merger", 2026-10-31, https://aibio.space/companies/imagenebio/